Dan Roden
-
October 24, 2019
Article examines need for genotyping after stenting
Genotyping can improve outcomes in patients who require anti-platelet therapy following stent placement to open narrowed or blocked coronary arteries and prevent a heart attack. -
October 17, 2019
Peterson, Roden honored for translational medicine efforts
Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics. -
September 25, 2019
Study identifies targeted therapy’s cardiac risks
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths. -
May 22, 2019
Van Driest lands young investigator award from the American Society for Clinical Pharmacology and Therapeutics
Sara Van Driest, MD, PhD, assistant professor of Pediatrics and Medicine, recently received the 2019 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics. -
June 21, 2018
Roden’s circulatory diseases research honored
Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada. -
June 21, 2018
Roden’s circulatory diseases research honored
Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada. -
June 14, 2018
VUMC joins research network to fight atrial fibrillation
Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.